Chemomab Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update
Chemomab Therapeutics (Nasdaq: CMMB), a clinical stage biotechnology company focused on developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, has announced that it will release its second quarter 2024 financial results on August 21, 2024, at 7:00 am Eastern Time. The company will also provide a business update along with the financial report. Investors interested in discussing the financial results or business update after the earnings release can contact the company at IR@chemomab.com.
Chemomab Therapeutics (Nasdaq: CMMB), un'azienda biotecnologica in fase clinica che si concentra sullo sviluppo di terapie innovative per le malattie fibro-infiammatorie con un alto bisogno non soddisfatto, ha annunciato che pubblicherà i suoi risultati finanziari per il secondo trimestre del 2024 il 21 agosto 2024 alle 7:00 ora orientale. L'azienda fornirà anche un aggiornamento commerciale insieme al rapporto finanziario. Gli investitori interessati a discutere i risultati finanziari o l'aggiornamento commerciale dopo la pubblicazione dei risultati possono contattare l'azienda all'indirizzo IR@chemomab.com.
Chemomab Therapeutics (Nasdaq: CMMB), una empresa biotecnológica en etapa clínica que se centra en el desarrollo de terapias innovadoras para enfermedades fibro-inflamatorias con una alta necesidad no satisfecha, ha anunciado que publicará sus resultados financieros del segundo trimestre de 2024 el 21 de agosto de 2024 a las 7:00 a.m. hora del Este. La empresa también proporcionará una actualización comercial junto con el informe financiero. Los inversores interesados en discutir los resultados financieros o la actualización comercial después del lanzamiento de ganancias pueden contactar a la empresa en IR@chemomab.com.
Chemomab Therapeutics (Nasdaq: CMMB)는 높은 unmet need가 있는 섬유 염증 질환을 위한 혁신적인 치료제를 개발하는 데 주력하는 임상 단계의 생명공학 회사로, 2024년 2분기 재무 결과를 2024년 8월 21일 동부 시간 기준 오전 7:00에 발표할 것이라고 발표했습니다. 회사는 재무 보고서와 함께 비즈니스 업데이트도 제공할 것입니다. 실적 발표 후 재무 결과 또는 비즈니스 업데이트에 대해 논의하고 싶은 투자자들은 IR@chemomab.com으로 회사에 문의할 수 있습니다.
Chemomab Therapeutics (Nasdaq: CMMB), une entreprise de biotechnologie en phase clinique axée sur le développement de thérapies innovantes pour les maladies fibro-inflammatoires avec un grand besoin non satisfait, a annoncé qu'elle publiera ses résultats financiers du deuxième trimestre 2024 le 21 août 2024 à 7h00, heure de l'Est. L'entreprise fournira également une mise à jour commerciale avec le rapport financier. Les investisseurs intéressés à discuter des résultats financiers ou de la mise à jour commerciale après la publication des résultats peuvent contacter l'entreprise à l'adresse IR@chemomab.com.
Chemomab Therapeutics (Nasdaq: CMMB), ein biopharmazeutisches Unternehmen in klinischer Phase, das sich auf die Entwicklung innovativer Therapeutika für fibro-inflammatorische Erkrankungen mit hohem ungedecktem Bedarf konzentriert, hat angekündigt, dass es am 21. August 2024 um 7:00 Uhr Eastern Time seine Finanzergebnisse für das zweite Quartal 2024 veröffentlichen wird. Das Unternehmen wird auch ein Geschäftsupdate zusammen mit dem Finanzbericht bereitstellen. Investoren, die an einer Diskussion der finanziellen Ergebnisse oder des Geschäftsupdates nach der Veröffentlichung der Ergebnisse interessiert sind, können das Unternehmen unter IR@chemomab.com kontaktieren.
- Timely reporting of quarterly financial results
- Offering investor communication opportunity post-earnings release
- None.
TEL AVIV, Israel, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (“Chemomab” or the “Company”), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced the company will issue a press release reporting its second quarter 2024 financial results and providing a business update on August 21, 2024, at 7:00 am Eastern Time.
Investors who would like to discuss the financial results or business update after the earnings release has been issued are invited to contact the company at IR@chemomab.com.
About Chemomab Therapeutics Ltd.
Chemomab is a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Based on the unique and pivotal role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody that neutralizes CCL24 activity. In clinical and preclinical studies, CM-101 has been shown to have a favorable safety profile and has been generally well-tolerated to date, with the potential to treat multiple severe and life-threatening fibro-inflammatory diseases. Chemomab has reported positive results from four clinical trials of CM-101 in patients, including a Phase 2 trial in patients with primary sclerosing cholangitis (PSC), a Phase 2a liver fibrosis trial in patients with metabolic dysfunction-associated steatohepatitis (MASH), a Phase 1b study in patients with metabolic dysfunction–associated fatty liver disease (MAFLD) and an investigator-initiated study in patients with severe lung injury. Chemomab’s CM-101 program for the treatment of systemic sclerosis is Phase 2-ready with an open U.S. IND. For more information, visit www.chemomab.com.
Contact:
Media & Investors:
Chemomab Therapeutics
Barbara Lindheim
Consulting Vice President
Investor & Public Relations,
Strategic Communications
Phone: +1 917-355-9234
barbara.lindheim@chemomab.com
IR@chemomab.com
FAQ
When will Chemomab Therapeutics (CMMB) release its Q2 2024 financial results?
What is Chemomab Therapeutics' (CMMB) focus area?
How can investors discuss Chemomab Therapeutics' (CMMB) Q2 2024 results?
What information will Chemomab Therapeutics (CMMB) provide along with its Q2 2024 financial results?
